TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch

Benzinga Logo Benzinga • •By Vandana Singh
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch

The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.

Insights
OXY.WS   positive

Berkshire agreed to acquire OxyChem's petrochemical unit for $9.7 billion


LLY   positive

Potential for faster FDA review and accelerated market entry for their weight loss drug